How much does a box of Cemiplimab cost?

Cemiplimab (Cemiplimab) is an innovative anti-cancer drug that belongs to the field of immunotherapy. It was jointly developed by U.S. pharmaceutical company Regeneron Pharmaceuticals and Sanofi, a French company, and has been approved to treat certain types of cancer. The following is a brief introduction to cimepilimab:

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.

Cimeplimab's mechanism of action is to enhance the immune system's attack on cancer through immune checkpoint inhibition. Immune checkpoints are biological molecules commonly used to regulate the activity of the immune system. However, in some types of cancer, overactivity of immune checkpoints inhibits the immune system's attack on cancer cells, allowing the cancer to evade immune system clearance. Cimepilimab works by blocking the binding of the PD-1 receptor (programmed death-1) to its ligand PD-L1 (programmed death ligand 1). This helps activate TT cells so that they can recognize and attack cancer cells more effectively.

Cimepilimab represents an important innovation in the field of immunotherapy, providing a new treatment option for patients who are insensitive to or unsuitable for traditional treatments. It has achieved significant results in improving patients' survival prospects, reducing symptoms and improving quality of life. Patients should consult their physician before receiving treatment to understand the indications and specific treatment plan to ensure optimal efficacy and safety under medical supervision.